Literature DB >> 2846688

Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies.

M Steinitz1, S Tamir, J E Frödin, A K Lefvert, H Mellstedt.   

Abstract

Patients who undergo immunotherapy with a murine anti-colon carcinoma mAb (mAb17-1A) generate high titers of anti-idiotype and anti-isotype antibodies. Specifically selected anti-idiotypic antibodies that elicit in vivo a humoral and a cellular immune response against the nominal Ag can be used as surrogate Ag for immunization. We established from the B lymphocytes of a treated patient a series of EBV-transformed cell lines. Three weeks after immortalization, the cells were selected for production of antibodies (Ab2) against the Fab fragment of the murine mAb17-1A. The selected cells were cloned and screened by ELISA for specific anti-mAb17-1A idiotypic antibodies. Thirty-six out of 89 clones were anti-idiotypes. Cell culture supernatants and the purified Ig derived from 10 clones completely inhibited the specific binding of radiolabeled mAb17-1A to HT-29 colon carcinoma cells thus resembling Ab2-gamma anti-idiotypes. These cell lines which grow now in culture for 18 mo, continuously secrete IgG,K anti-Ab1-idiotype mAb. Human anti-idiotypic mAb might be candidates for vaccines when the nominal Ag itself is not available or cannot be used as such.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846688

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma.

Authors:  H Mellstedt; J E Frödin; P Ragnhammar; G Masucci; J Shetye; B Christensson; P Biberfeld; J Makower; P Pihlstedt; B Cedermark
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Separation of rare cell subpopulations with the aid of biotin-labelled ligands.

Authors:  M Steinitz; A Livoff; S Tamir; T Brenner
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

3.  The role of humoral and cellular immunity in patients developing human anti-murine immunoglobulin antibody responses after radioimmunotherapy.

Authors:  C Kosmas; S Man; A A Epenetos; N S Courtenay-Luck
Journal:  Br J Cancer Suppl       Date:  1990-07

4.  Human response against NP-4, a mouse antibody to carcinoembryonic antigen: human anti-idiotype antibodies mimic an epitope on the tumor antigen.

Authors:  M J Losman; H J Hansen; R M Sharkey; D M Goldenberg; M Monestier
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 5.  Chemotherapy and immunotherapy of colorectal cancer.

Authors:  G Masucci; P Ragnhammar; J E Frödin; A L Hjelm; P Wersäll; J Fagerberg; A Osterborg; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

6.  The clinical significance of HAMA in patients treated with mouse monoclonal antibodies.

Authors:  J E Frödin; A K Lefvert; H Mellstedt
Journal:  Cell Biophys       Date:  1992 Aug-Dec

7.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

Authors:  J Fagerberg; J E Frödin; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

8.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?

Authors:  J Fagerberg; J E Frödin; P Ragnhammar; M Steinitz; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

9.  Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.

Authors:  J Fagerberg; M Steinitz; H Wigzell; P Askelöf; H Mellstedt
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

Review 10.  Monoclonal antibodies for cancer immunotherapy.

Authors:  Louis M Weiner; Madhav V Dhodapkar; Soldano Ferrone
Journal:  Lancet       Date:  2009-03-21       Impact factor: 79.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.